Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Monoclonal Gammopathy of Undetermined Significance

• A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple My
• A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
• Daratumumab for Polyneuropathy Associated With MGUS
• Isatuximab in Type I Cryoglobulinemia
• Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
• Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
• Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
• Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
• Rifaximin in Patients With Monoclonal Gammopathy
• Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
• Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
• Imaging Studies and the Development of Multiple Myeloma
• Imaging in MGUS, SMM and MM
• Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance
• RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
• Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction